Abstract
Get full access to this article
View all access options for this article.
References
1.Editorial , “Insider Trading Versus Medical Professionalism,” The Lancet 366 , no. 9488 (2005 ): 781 .
2.
Horwich
A.
, “The Clinical Trial Participant as an Insider Trader: A Legal and Policy Analysis,” Journal of Health Law 39 , no. 1 (2006 ): 77 –116 .
3.
Arnst
C.
, “How Drug News Leaks to Investors,” BusinessWeek Magazine , May 6, 2002 , available at <http://businessweek.com/magazine/content/02_18/b3781048.htm> (last visited April 6, 2012 ).
4.American Society of Clinical Oncology, (ASCO) , “Meeting Abstracts,” Journal of Clinical Oncology 25 , no. 18S (2007 ).
5.
Pharmboy
A.
, “ASCO Abstracts Trigger Trading,” Terra Sig Online , May 19, 2007 , available at <http://scienceblogs.com/terrasig/2007/05/asco_abstracts_trigger_trading.php> (last visited April 6, 2012 );
Cortez
M.
Randall
T.
, “What Cancer Doctors Know Kills ASCO's Book for Insider Trading,” Bloomberg: Health Care , May 14, 2008 , available at <http://www.bloomberg.com/apps/news?pid=newsarchive&sid=ayfdiC9VAn80&refer=healthcare (last visited April 12, 2012 );
Lowe
D.
, “Is There Any Insider Trading Going On in Drug Stocks,” Seeking Alpha , December 15, 2008 , available at <http://seekingalpha.com/article/110778-is-there-any-insider-trading-going-on-in-drug-stocks> (last visited April 6, 2012 ).